Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.11 USD
-0.03 (-0.27%)
Updated May 26, 2023 04:00 PM ET
After-Market: $11.12 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
FOLD 11.11 -0.03(-0.27%)
Will FOLD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Company News for May 11, 2023
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
Icosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for FOLD
Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive
SVB Securities Sticks to Its Buy Rating for Amicus (FOLD)
Berenberg Bank Keeps Their Hold Rating on Amicus (FOLD)
Amicus Therapeutics (FOLD) Q1 2023 Earnings Call Transcript
Amicus Therapeutics: Q1 Earnings Snapshot